Peptide guide 03 · Safety

Pharmaceutical, compounded or research grade: what actually differs

The same peptide name can describe three very different products. An FDA-approved drug has trial data and batch testing behind it. A compounded version is made by a pharmacy under lighter rules and is not FDA-approved. A research-use-only vial is a chemical with no required testing for sterility, endotoxin or the amount inside.

8 minute read 9 sources Reviewed October 2026
The short version
Pharmaceutical An approved drug from a licensed manufacturer

Trial data reviewed by the FDA, made under drug manufacturing rules, tested batch by batch, sold with a label and usually a prefilled pen.

Wegovy, Zepbound, Egrifta
Compounded Mixed by a pharmacy from bulk ingredient

Legal when the ingredient qualifies. A 503B facility follows drug manufacturing rules; a 503A pharmacy follows state rules. Neither product is FDA-approved.

Compounded semaglutide in narrow cases
Research use only A chemical sold for lab experiments

No approval, no manufacturing standard, no required sterility or endotoxin testing, and a label that says it is not for people.

BPC-157, TB-500, retatrutide powders
Quality control

Eight checkpoints between a raw ingredient and your syringe

Pick a source and tap any row. Approved drugs pass every checkpoint by law. A research-use-only vial is required to pass none of them.

Pick a source
CheckpointFDA503B503ARUO
Required Partly or sometimes Not requiredTap a row for details
Research use only · Not required
Sterility and endotoxin tested

Optional. A freeze-dried powder sold as a chemical has no sterility or endotoxin requirement.

0 of 8checkpoints fully required for a research use only product.
Side by side

The full comparison

Costs are described in general terms only. This site does not list prices or sellers.

FDA-approved vs compounded vs research-use-only peptides
FDA-approvedCompounded (503A / 503B)Research use only
Who regulates itFDAState pharmacy boards (503A); FDA (503B)Nobody before sale
PrescriptionRequiredRequired for 503A; 503B may supply clinicsNone
Evidence behind itTrials for this productBorrowed from the approved drug, if one existsOften animal studies only
Manufacturing standardCurrent good manufacturing practice503B: same. 503A: USP 797, state-enforcedNone
Sterility testingEvery batch503B: before release. 503A: some preparationsOptional
Endotoxin testingEvery batch503B: before release. 503A: some preparationsOptional
How it arrivesPrefilled pen or labeled vialVial and syringes, sometimes pensFreeze-dried powder in a vial
Cost, in generalHighest cash price; insurance may coverUsually lower cash price than brandLowest price per milligram
If something goes wrongAdverse-event reporting, recalls, label changesState complaint; 503B reports to FDALittle or no recourse
Evidence

What testing and reporting have found

990

reports of adverse events with compounded semaglutide received by the FDA as of May 31, 2026, and more than 730 for compounded tirzepatide

FDA
28 to 39%

more semaglutide than the label stated, in vials bought from illegal online sellers in a 2024 test-buy study

JMIR 2024
28 days

how long the FDA says a multi-dose vial should be used after first puncture, even if drug is left

FDA
2

salt forms, semaglutide sodium and semaglutide acetate, that the FDA says are different active ingredients with no known lawful basis for compounding

FDA
One study in detail

Test-buying semaglutide without a prescription

Researchers at the University of Pécs and UC San Diego placed six orders for semaglutide with illegal online pharmacies that sold it without a prescription. Three vials arrived; none of the three ordered pens did. All three vials failed more than half of a visual inspection checklist, and lab testing found 28.6% to 38.7% more semaglutide than the label stated.

A larger 2026 preprint, not yet peer reviewed, pooled 6,441 test results across 14 peptides from a commercial testing database and reported that 41.6% to 71.1% of samples failed basic quality criteria, depending on the method, with measurable endotoxin in 15%. Treat those numbers as provisional until the paper is published.

6 ORDERS 3 vials arrived 3 pens never did LABEL Measured: 28 to 39% over label
What can go wrong

Four risks, and where each one concentrates

Measuring errors

Approved GLP-1 pens click to a fixed amount. Vials and insulin syringes mean converting milligrams to milliliters to units, and the FDA has received reports, some with hospital stays, of people drawing the wrong amount.

Most common with compounded and research vials
Wrong or extra substance

A product can hold more or less drug than labeled, a different salt form, a related peptide fragment, or no active drug at all. Counterfeit Ozempic pens have also reached the US supply chain.

Research products, counterfeit pens, unlicensed online sellers
Bacteria and endotoxin

An injected product that is not sterile can cause abscesses or bloodstream infections. Endotoxin, a fragment of bacterial cell walls, can cause fever and chills even when the bacteria are dead.

Highest where no sterility or endotoxin testing is required
No one to report to

With an approved drug, side-effect reports reach the manufacturer and the FDA and can change the label. A research chemical has no reporting system, so problems stay invisible.

Research use only
Before anything is injected

Six questions for your prescriber or pharmacist

If a clinic or pharmacy cannot answer these, that tells you something about the product.

  1. 1Is this an FDA-approved product, or is it compounded? If compounded, by a 503A pharmacy or a 503B outsourcing facility?
  2. 2What is the exact active ingredient, including the salt form, and does it match the approved drug?
  3. 3Which state licenses the pharmacy, and can I look the license up?
  4. 4Was this batch tested for sterility and endotoxin, and can I see the result?
  5. 5How is the amount measured: a pen, or a vial and syringe? If a syringe, how many units equal one dose on my prescription?
  6. 6How long can the vial be used after first puncture, and how should it be stored?
Keep going

Peptides mentioned in this guide

The Staate peptide brief

FDA actions and test results, as they happen

Warning letters, recalls, compounding rules and new quality data, explained with the source linked. Daily and free. We do not sell peptides or take money from sellers.

Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy?
No. It may contain the same active molecule, but the finished product has not been reviewed or approved by the FDA, it is made to different standards, and it usually comes as a vial you draw from with a syringe rather than a prefilled pen. The FDA has also warned that some compounders used semaglutide sodium or semaglutide acetate, which are different active ingredients from the approved drug.
Is a 503B outsourcing facility safer than a 503A pharmacy?
The rules are stricter. 503B facilities register with the FDA, follow current good manufacturing practice, test batches for sterility and endotoxin before release, and report adverse events. 503A pharmacies are regulated mainly by state boards and are exempt from manufacturing rules. Quality still varies between individual facilities in both groups.
Are research peptides the same molecule as the drug?
Sometimes, sometimes not. Without independent testing of the specific vial, you cannot know the identity, amount, purity or sterility. Testing of unregulated semaglutide has found vials with more drug than labeled and endotoxin contamination.
Why are research peptides so much cheaper?
They skip the costs that make a drug a drug: clinical trials, manufacturing under inspection, batch release testing for sterility and endotoxin, stability studies, and adverse-event systems. The price difference is mostly the cost of those checks.
Does a certificate of analysis make a research peptide safe?
No. A certificate of analysis describes one sample from one batch, often tested by a lab the seller chose. It usually does not cover sterility or endotoxin. Our guide to reading a COA explains what each section can and cannot show.
Can a pharmacy compound any peptide my doctor prescribes?
No. Under section 503A the bulk ingredient must have a USP monograph, be part of an approved drug, or be on the 503A bulks list. Most research peptides, including BPC-157, meet none of these as of October 2026.